Severe embryolethality of artesunate related to pharmacokinetics following intravenous and intramuscular doses in pregnant rats
Authors:
- 22 October 2009
- journal article
- research article
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 86 (5) , 385-393
Abstract
Artesunate (AS), a rapid, effective, and safe antimalarial drug, has been used for the treatment of malaria for decades. However, severe embryolethality was found for injectable AS in pregnant animals. In the present study, pregnant rats were selected and dosed with AS (GMP product) intravenously (IV) and intramuscularly (IM) at varied doses daily for 13 days from gestation day (GD) 6 to 18. In addition, a toxic dose of 1.2 mg/kg/day was subsequently tested in the GD 6–10, GD 11–15, and GD 16–20 periods of rat pregnancy. A pharmacokinetic study was also conducted to evaluate the bioavailability of AS following the IM administrations. Results showed that no significant adverse effects were found in maternal rats. All of the fetuses were either damaged or reabsorbed by placentas in treated pregnant rats, but doses did not show an adverse effect at 0.4 and 0.5 mg/kg after IV and IM administrations, respectively. The survival rate of fetuses is dose‐dependent and the 50% fetus re‐absorption doses (FRD50) were 0.61 and 0.60 mg/kg following the IV and IM, respectively. The most drug‐sensitive period, showing severe embryotoxicity, was between GD 11 and 15 for injectable AS. When calculated with total concentrations of AS and dihydroartemisinin, an active metabolite of AS, the bioavailability of 97.8% after intramuscular injection was fulfilled to a bioequivalence of that in intravenous treatment. The fact that injectable AS exhibited severe embryolethality after both IV and IM injections seems related to their comparable pharmacokinetic profiles that indicate high peak concentrations in pregnant animals. Birth Defects Res (Part B) 86:385–393, 2009. Published 2009 Wiley‐Liss, Inc.Keywords
This publication has 30 references indexed in Scilit:
- Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte countBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2008
- Artesunate: developmental toxicity and toxicokinetics in monkeysBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2008
- Toxicity of artemisinin [Artemisia annua L.] in two different periods of pregnancy in Wistar ratsReproductive Toxicology, 2008
- Artesunate, artemether or quinine in severePlasmodium falciparummalaria?Expert Review of Anti-infective Therapy, 2007
- Artesunate plus sulfadoxine–pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern SudanTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Developmental toxicity of artesunate and an artesunate combination in the rat and rabbitBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2004
- Inhibitory Effects of Artesunate on Angiogenesis and on Expressions of Vascular Endothelial Growth Factor and VEGF Receptor KDR/flk-1Pharmacology, 2004
- A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malariaBritish Journal of Clinical Pharmacology, 1998
- Pharmacokinetics of Artemisinin and Artesunate after Oral Administration in Healthy VolunteersThe American Journal of Tropical Medicine and Hygiene, 1997
- DNA Repair Works Its Way to the Top1994